SCHEMBL238236

SCHEMBL238236

Cc1cc2ncc3cc(-c4ccccc4C#N)c(Cl)nc3n2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.42
GABRG2 P18507 4/20 0.42
GABRB3 P28472 4/20 0.42
GABRA2 P47869 4/20 0.42
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
HPGD P15428 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
KDM4E B2RXH2 6/20 0.36
PDE10A Q9Y233 1/20 0.36
NPSR1 Q6W5P4 4/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RXFP1 Q9HBX9 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238671 0.85 NPC1 (0.41) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL238754 0.85 NPC1 (0.41) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL239018 0.83 NPC1 (0.40) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL235500 0.83 KMT2A (0.40) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL235881 0.81 RAB9A (0.48) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL239054 0.81 TSHR (0.45) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL237538 0.81 NPC1 (0.46) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL240488 0.81 KMT2A (0.39) GABRA1GABRG2GABRB3GABRA2NPC1
SCHEMBL240395 0.80 HSD11B1 (0.41) NPC1RAB9AHPGDKMT2ASMN1; SMN2
SCHEMBL238176 0.79 MAOB (0.40) NPC1RAB9AHPGDKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 GABRA1 4303/4885GABRG2 3869/4885GABRB3 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.